7-bromo-4-chloroquinolin-2-amine | 68050-38-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-bromo-4-chloroquinolin-2-amine
• 英文别名: 2-Amino-7-bromo-4-chloroquinoline
• CAS: 68050-38-4
• 化学式: C₉H₆BrClN₂
• 分子量: 257.517
• InChiKey: MZELRJFWXXYUIM-UHFFFAOYSA-N

物化性质

• 沸点：
  382.4±37.0 °C(Predicted)
• 密度：
  1.749±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-bromo-4-chloroquinolin-2-amine 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 3.5h， 生成 8-bromo-5-chloro-imidazo[1,2-a]quinoline-2-carboxylic acid
  参考文献：
  名称：

  Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles

  摘要：

  4H-Imidazo[2,1-c][1,4]benzoxazine-2-carboxylic acid (3) was found to possess potent activity in the IgE-induced rat passive cutaneous anaphylaxis model which may be predictive of clinical antiallergic activity. Compared to disodium cromoglycate (DSCG, 1), 3 was less active following iv administration but unlike DSCG showed very significant oral activity. To explore the structural requirements for this activity, a range of tricyclic compounds was prepared and their activities were measured. Individual 2-carboxylic acids derived from imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles showed iv activities up to 10(3) times as potent as DSCG and many of them showed significant oral activity. From these, imidazo[1,2-a]quinoxaline-2-carboxylic acid 114 has been chosen for further development.

  DOI：

  10.1021/jm00401a009
• 作为产物：
  描述：

  7-溴-4-氯喹啉 在 对甲苯磺酰氯 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 7-bromo-4-chloroquinolin-2-amine
  参考文献：
  名称：

  [EN] NLRP3 MODULATORS
  [FR] MODULATEURS DE NLRP3

  摘要：

  本发明提供了化合物的公式(I)，(II)或(III)：(I)，(II)，(III)，其中所有变量均如本文所定义。这些化合物是NLRP3的调节剂，可用作治疗增殖性疾病的药物，例如在受试者（例如人类）中的癌症。

  公开号：

  WO2020150116A1

文献信息

• Novel imidazoquinolines
  申请人：Roussel Uclaf

  公开号：US04279912A1

  公开（公告）日：1981-07-21

  Novel imidazoquinolines of the formula ##STR1## wherein X and Y are individually selected from the group consisting of hydrogen, halogen and alkoxy of 1 to 5 carbon atoms, Z is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms optionally substituted with at least two hydroxyls or protected hydroxyls and ##STR2## n is an integer from 1 to 6 and R.sub.1 and R.sub.2 are individually alkyl of 1 to 5 carbon atoms and taken together with the nitrogen to which they are attached form a saturated heterocyclic ring containing 4 to 6 carbon atoms and optionally interrupted by another heteroatom which further heteroatom is optionally substituted with alkyl of 1 to 5 carbon atoms and non-toxic, pharmaceutically acceptable salts thereof having antiallergic and bronchodilatory activity and their preparations.

  新型咪唑喹啉的化学式为##STR1##其中X和Y分别选自氢、卤素和1至5个碳原子的烷氧基组成的群，Z选自氢、1至5个碳原子的烷基，可选地被至少两个羟基或保护羟基取代，并且##STR2##n是1至6的整数，R.sub.1和R.sub.2分别是1至5个碳原子的烷基，并与它们连接的氮一起形成含有4至6个碳原子的饱和杂环环，可选地被另一个杂原子中断，该另一个杂原子可选地被1至5个碳原子的烷基取代，以及其无毒、药学上可接受的盐，具有抗过敏和支气管扩张活性以及它们的制备。
• COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER
  申请人：CanBas Co., Ltd.

  公开号：EP3088397A1

  公开（公告）日：2016-11-02

  Substituted azole diones (II) and (III) are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making the invention compounds are provided. The invention provides substituted azole diones (II) and (III) to treat cell proliferation disorders. The invention includes the substituted azole diones (II) and (III) for use to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the cell cycle G2- checkpoint-abrogating substituted azole diones (II) and (III) for use to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.

  本发明提供的取代唑二酮类化合物(II)和(III)可杀死细胞、抑制细胞增殖、抑制细胞生长、减弱细胞周期 G2 检查点和/或导致适应 G2 细胞周期停滞。提供了制造本发明化合物的方法。本发明提供了用于治疗细胞增殖障碍的取代唑二酮类化合物（II）和（III）。本发明包括取代的唑二酮(II)和(III)，用于选择性地杀死或抑制癌细胞，而无需额外的抗癌治疗。本发明包括细胞周期G2-检查点消减取代的唑二酮(II)和(III)，用于选择性地使癌细胞对DNA损伤试剂、治疗和/或其它类型的抗癌试剂敏感。
• N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
  申请人：CanBas Co., Ltd.

  公开号：EP3567035A1

  公开（公告）日：2019-11-13

  Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.

  本发明提供了新型取代唑二酮类化合物，可杀死细胞、抑制细胞增殖、抑制细胞生长、减弱细胞周期 G2 检查点和/或导致细胞周期 G2 停滞。本发明还提供了制造和使用本发明化合物的方法。本发明提供了用于治疗细胞增殖障碍的取代唑二酮类化合物。本发明包括使用取代的唑二酮选择性地杀死或抑制癌细胞，而无需额外的抗癌治疗。本发明包括使用细胞周期G2-检查点抑制取代的唑二酮类化合物选择性地使癌细胞对DNA损伤试剂、治疗和/或其它类型的抗癌试剂敏感。
• NLRP3 modulators
  申请人：Innate Tumor Immunity, Inc.

  公开号：US11344543B2

  公开（公告）日：2022-05-31

  The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

  本发明提供了式 (I) 的化合物：(I)，其中所有变量如本文所定义。这些化合物是 NLRP3 的调节剂，可用作治疗受试者（例如人类）增殖性疾病（如癌症）的药物。
• WO2020150115A5
  申请人：——

  公开号：WO2020150115A5

  公开（公告）日：2022-09-05